Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
However, it has faced criticism for its high pricing and extended market exclusivity, which ended in January 2023.Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.'s (NYSE:ABBV) Humira, one of the world's most expensive and widely used drugs.
加州蓝盾公司通过一项具有突破意义的交易，彻底降低了亚马逊公司（纽交所：ABBV）旗下荷兰美拉（Humira）生物类似物的价格，从而改变了药店的景观，这是全球价格最昂贵且使用最广泛的药物之一。
Humira, approved by the FDA in 2002, has long dominated the market, treating conditions like arthritis and Crohn's disease.
艾伯维公司的阿瑞士药物Humira获得FDA批准于2002年，长期占据市场主宰地位，用于治疗关节炎和克罗恩病等疾病。
Also Read: AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability.
阅读更多：尽管面临生物类似物竞争和挑战，艾伯维公司的关节炎药物Humira仍然保持市场主导地位，挑战生物类似物行业的生存能力。
However, it has faced criticism for its high pricing and extended market exclusivity, which ended in January 2023.
然而，该药物由于定价过高和市场独占权的延长而受到批评，这一独占权于2023年1月结束。
Blue Shield, which processes around 40,000 Humira prescriptions annually, spends more on the drug than any other medication for its members, making this price-cutting move both timely and essential for addressing the rising cost of healthcare.
蓝盾公司每年处理约40,000份Humira处方，为其会员花费在该药物上的金额超过其他任何药物，因此，这一降价举措及时且十分必要，以应对医疗成本上涨。
The nonprofit health plan announced that it would purchase Fresenius Kabi's FDA-approved biosimilar adalimumab-aacf at a net price of $525 per monthly dose, a significant reduction from Humira's market-reported price of $2,100.
非营利性健康计划宣布将以每月$525的净价格购买Fresenius Kabi的FDA批准的生物类似物阿达利单抗-aacf，这比Humira市场报价的$2,100低得多。
The deal, facilitated by Evio Pharmacy Solutions, aims to eliminate excessive markups typically imposed by pharmacy benefit managers (PBMs) in the current drug supply chain.
由Evio药店解决方案推动的交易旨在消除目前药物供应链中通常由药店利润管理人员（PBMs）强加的过高加价。
The new pricing model is part of Blue Shield's Pharmacy Care Reimagined initiative, which rethinks traditional PBM structures to ensure more transparent and affordable pricing.
新的定价模式是蓝盾公司“药房护理重塑”计划的一部分，重新思考传统的PBm结构，以确保更透明和负担得起的定价。
The aligned incentives and simplified supply chain have enabled Blue Shield to provide Fresenius Kabi's biosimilar to its members. Starting in January 2025, most commercial members are expected to pay $0 out of pocket.
通过奖励措施和简化供应链，Blue Shield得以向其会员提供Fresenius Kabi的生物类似药品。预计从2025年1月开始，大多数商业会员将不需支付任何费用。
This move sets a critical precedent as the pharmaceutical industry approaches a "biosimilar cliff," with more low-cost alternatives entering the market.
这一举动为药品行业在接近"生物类似药品悬崖"时树立了关键的先例，更多低成本替代品进入市场。
Last month, UnitedHealth Group Inc. (NYSE:UNH) said it would remove Humira from some of its preferred reimbursement lists starting January 1, 2025. The company will recommend lower-cost biosimilar versions instead.
上个月，UnitedHealth Group Inc.（纽交所：UNH）表示将于2025年1月1日起从部分首选报销名单中移除Humira。该公司将推荐更低成本的生物类似药品版本。
Price Action: ABBV stock is down 0.45% at $195.93 at the last check on Thursday.
股价走势：艾伯维公司股票在周四最后交易时下跌0.45%，报195.93美元。
- Amazon's Profitable Essential Merchandise, Efficiency Gains Set To Drive Growth: Analyst
- 亚马逊盈利的基本商品，效率提升有望推动增长：分析师
Photo via Wikimedia Commons
照片通过Wikimedia Commons